Jialei Hao, Xinzhi Zhao, Chun Wang, Xianghui Cao, Yang Liu
{"title":"Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy.","authors":"Jialei Hao, Xinzhi Zhao, Chun Wang, Xianghui Cao, Yang Liu","doi":"10.1021/acs.bioconjchem.4c00242","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer immunotherapy has yielded remarkable results across a variety of tumor types. Nevertheless, the complex and immunosuppressive microenvironment within solid tumors poses significant challenges to established therapies such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell (CAR-T) therapy. Within the milieu, tumor-associated macrophages (TAMs) play a significant role by directly suppressing T-cell functionality and fostering an immunosuppressive environment. Effective regulation of TAMs is, therefore, crucial to enhancing the efficacy of immunotherapies. Various therapeutic strategies targeting TAM modulation have emerged, including blocking TAM recruitment, direct elimination, promoting repolarization toward the M1 phenotype, and enhancing phagocytic capacity against tumor cells. The recently introduced CAR macrophage (CAR-M) therapy opens new possibilities for macrophage-based immunotherapy. Compared with CAR-T, CAR-M may demonstrate superior targeting and infiltration capabilities toward solid tumors. This review predominantly delves into the origin and development process of TAMs, their role in promoting tumor growth, and provides a comprehensive overview of immunotherapies targeting TAMs. It underscores the significance of regulating TAMs in bolstering antitumor therapies while discussing the potential and challenges of developing TAMs as targets for immunotherapy.</p>","PeriodicalId":29,"journal":{"name":"Bioconjugate Chemistry Bioconjugate","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioconjugate Chemistry Bioconjugate","FirstCategoryId":"1","ListUrlMain":"https://doi.org/10.1021/acs.bioconjchem.4c00242","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer immunotherapy has yielded remarkable results across a variety of tumor types. Nevertheless, the complex and immunosuppressive microenvironment within solid tumors poses significant challenges to established therapies such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell (CAR-T) therapy. Within the milieu, tumor-associated macrophages (TAMs) play a significant role by directly suppressing T-cell functionality and fostering an immunosuppressive environment. Effective regulation of TAMs is, therefore, crucial to enhancing the efficacy of immunotherapies. Various therapeutic strategies targeting TAM modulation have emerged, including blocking TAM recruitment, direct elimination, promoting repolarization toward the M1 phenotype, and enhancing phagocytic capacity against tumor cells. The recently introduced CAR macrophage (CAR-M) therapy opens new possibilities for macrophage-based immunotherapy. Compared with CAR-T, CAR-M may demonstrate superior targeting and infiltration capabilities toward solid tumors. This review predominantly delves into the origin and development process of TAMs, their role in promoting tumor growth, and provides a comprehensive overview of immunotherapies targeting TAMs. It underscores the significance of regulating TAMs in bolstering antitumor therapies while discussing the potential and challenges of developing TAMs as targets for immunotherapy.
通过调节肿瘤相关巨噬细胞进行癌症治疗的纳米免疫疗法的最新进展》(Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy)。
癌症免疫疗法已在多种肿瘤类型中取得了显著效果。然而,实体瘤内复杂的免疫抑制微环境给免疫检查点阻断(ICB)和嵌合抗原受体 T 细胞(CAR-T)疗法等既有疗法带来了巨大挑战。在这种环境中,肿瘤相关巨噬细胞(TAMs)通过直接抑制 T 细胞功能和营造免疫抑制环境发挥着重要作用。因此,有效调节 TAMs 对提高免疫疗法的疗效至关重要。针对 TAM 调节的各种治疗策略已经出现,包括阻断 TAM 招募、直接清除、促进向 M1 表型的再极化,以及增强对肿瘤细胞的吞噬能力。最近推出的 CAR 巨噬细胞(CAR-M)疗法为基于巨噬细胞的免疫疗法提供了新的可能性。与CAR-T疗法相比,CAR-M疗法对实体瘤的靶向性和浸润能力更强。这篇综述主要探讨了TAMs的起源和发展过程、它们在促进肿瘤生长中的作用,并全面概述了针对TAMs的免疫疗法。它强调了调节 TAMs 对加强抗肿瘤疗法的重要意义,同时讨论了将 TAMs 开发为免疫疗法靶点的潜力和挑战。
期刊介绍:
Bioconjugate Chemistry invites original contributions on all research at the interface between man-made and biological materials. The mission of the journal is to communicate to advances in fields including therapeutic delivery, imaging, bionanotechnology, and synthetic biology. Bioconjugate Chemistry is intended to provide a forum for presentation of research relevant to all aspects of bioconjugates, including the preparation, properties and applications of biomolecular conjugates.